ResMed (RMD) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Key strategic themes and market positioning

• Targets a large, underpenetrated market of over 2.3 billion people with unmet sleep and breathing health needs, leveraging digital health, AI, and a robust five-year and 2030 strategy focused on innovation in hardware, software, and solutions.

• Operates as the global leader in sleep apnea therapy and connected health, with 27 million cloud-connected devices sold in 140 countries and over 20 billion nights of respiratory data in the cloud.

• Capitalizes on megatrends such as consumer-driven health tracking, preventative care, wearable tech for sleep detection, and the integration of AI/ML/GenAI in healthcare delivery.

• Integration of residential care software with core device business creates synergies in patient identification, therapy initiation, and ongoing engagement.

• Strategic partnerships, disciplined M&A, and expansion into high-growth markets are key pillars for future growth.

Digital health ecosystem and software integration

• Invested significantly in residential care software (Brightree, MEDIFOX DAN), creating strong synergies with core medtech business.

• Launching Snap Technologies for All in 2025 to expand resupply technology access beyond current platform users.

• Focuses on interoperability, enabling integration with major health systems (Epic, Cerner) and consumer health platforms (Apple HealthKit), with FDA clearance for sleep apnea detection on Apple and Samsung wearables expected to drive funnel growth.

• Prioritizes patient-centric design, improving experience, lowering delivery costs, and enhancing chronic disease outcomes.

• Utilizes real-world data and AI/ML analytics for large-scale clinical research, supporting evidence-based innovation.

Product innovation and adherence

• AirSense 11 platform features over-the-air updates, two-way communication, and a 50% uptake rate for the myAir app, doubling previous generation engagement.

• Achieves 87-90% adherence at 90 days when combining device, software, and provider engagement.

• Consumer-centric product design, such as the AirTouch N30i mask, has received high satisfaction and preference ratings in real-world studies.

• Peer-reviewed studies show CPAP adherence reduces mortality by 39% within three years in OSA patients.

• FDA clearance for sleep apnea detection on wearables is expected to drive significant funnel growth.